Pharmacokinetic Bridging Study of Tozorakimab Using an Accessorised Prefilled Syringe and Autoinjector in Patients with Respiratory Inflammation

The primary objective of this study is to evaluate the **pharmacokinetic** profile of Tozorakimab when administered using an accessorised prefilled syringe compared to an autoinjector. This is clinically relevant as it aims to determine the most effective and efficient delivery method for Tozorakimab, which is used in the treatment of conditions related to **respiratory** and **inflammation**. Understanding the pharmacokinetics is crucial for optimizing therapeutic outcomes and ensuring patient safety.

The clinical trial involves a total of **152 participants** who are being studied for conditions related to **respiratory** and **inflammation** issues. The study population includes both male and female subjects, with an age range that falls within the category code "3," which typically represents adults. Participants were selected without targeting any vulnerable populations, ensuring a general representation of the adult population. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The health status of participants is not explicitly mentioned, but the selection criteria suggest a focus on individuals with respiratory and inflammatory conditions.

The clinical trial is designed to evaluate the pharmacokinetic profile of **Tozorakimab** when administered via an accessorized prefilled syringe compared to an autoinjector. This study is a Phase 3 trial, focusing on conditions related to **respiratory** and **inflammation**. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is March 7, 2025, with an anticipated end date of September 26, 2025, indicating a total trial duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, adherence to the study protocol, and any adverse events. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the pharmacokinetic outcomes.

The expected length of participant involvement is aligned with the overall trial duration, approximately six months, contingent upon individual adherence to the study protocol. Conditions that may lead to early termination from the study include non-compliance with the study procedures, withdrawal of consent, or the occurrence of significant adverse events that compromise participant safety. The trial is conducted under strict ethical guidelines to ensure participant safety and data integrity.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used alongside the experimental medication. The absence of such information suggests that the focus is solely on the experimental treatment, although this cannot be confirmed without further details.

Details regarding the **participant compliance monitoring** and specific **dosing schedules** are not included in the provided data. The lack of this information indicates that the trial documentation may require additional input to ensure comprehensive understanding and adherence to the study protocol.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 7, 2025, with an estimated completion date of September 26, 2025. The efficacy assessment will be conducted through a series of evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial's focus is on obtaining reliable and valid results to determine the efficacy of the intervention under investigation.